Table 1 Baseline demographics and clinical characteristics.
Variables | All patients (n = 118) | AFP response (n = 49) | AFP non-response (n = 69) | P value |
|---|---|---|---|---|
Age (y) | ||||
Median (Range) | 48 (23–75) | 49 (30–74) | 47 (23–75) | 0.564 |
Sex | ||||
Male/Femal - No. (%) | 102 (86.4%)/16 (13.6) | 38 (77.6%)/11 (22.4%) | 64 (92.8%)/5 (7.2%) | 0.017 |
Etiology | ||||
HBV/HCV/Other - No. (%) | 105 (89%)/2 (1.7%)/11 (9.3%) | 41 (83.7%)/2 (4.1%)/6 (12.2%) | 64 (92.8%)/0 (0%)/5 (7.2%) | 0.146 |
Child-Pugh class | ||||
A/B - No. (%) | 107 (90.7%)/11 (9.3%) | 44 (89.8%)/5 (10.2%) | 63 (91.3%)/6 (8.7%) | 1 |
ECOG | ||||
0/1–2 - No. (%) | 30 (25.4%)/88 (74.6%) | 16 (32.7%)/33 (67.3%) | 14 (20.3%)/55(79.7%) | 0.139 |
BCLC stage | ||||
B/C - No. (%) | 19 (16.1%)/99 (83.9%) | 11 (24.5%)/38 (75.5%) | 8 (13%)/61 (87%) | 0.135 |
Disease burden | ||||
PVTT | ||||
No/yes - No. (%) | 71 (33.1%)/47 (66.9%) | 33 (67.3%)/16 (32.7%) | 38 (55.1%)/31 (44.9%) | 0.189 |
Extrahepatic spread | ||||
No/Yes - No. (%) | 73 (61.9%)/45 (38.1%) | 33 (67.3%)/16 (32.7%) | 40 (58%)/29 (42%) | 0.256 |
Baseline tumor size (cm) | ||||
Median (Range) | 10.8 (2.9–25.3) | 10.5 (3.5–22.1) | 11.7 (2.9–25.3) | 0.325 |
No. of HCC nodules | ||||
1/≥2/Diffused - No. (%) | 86 (72.9%)/22 (18.6%)/10 (8.5%) | 39 (79.6%)/8 (16.3%)/2 (4.1%) | 47 (68.1%)/14 (20.3%)/8 (11.6%) | 0.264 |
Baseline AFP (ng/ml) | ||||
<200/≥200 - No. (%) | 25 (21.2%)/93 (78.8%) | 12 (24.5%)/37 (75.5%) | 13 (18.8%)/56 (81.2%) | 0.459 |
Liver biopsy | ||||
Yes/No - No. (%) | 19 (16.1%)/99 (83.9%) | 9 (18.4%)/40 (81.6%) | 10 (14.5%)/59 (85.5%) | 0.573 |
Ascites | ||||
Yes/No - No. (%) | 22 (18.6%)/96 (81.4%) | 10 (20.4%)/39 (79.6%) | 12 (17.4%)/57 (82.6%) | 0.678 |
Laboratory values, mean (range) | ||||
Alanine aminotransferase (U/I) | 57.7 (10–395) | 62.9 (10–395) | 54.1 (13–236) | 0.355 |
Aspartate aminotransferase (U/I) | 77.6 (16–489) | 74.1 (16–362) | 80 (16–489) | 0.639 |
Total bilirubin, mg/dl | 17.9 (6.9–54) | 17.5 (7.1–362) | 18.2 (6.9–38.4) | 0.698 |
Platelets/mm3 | 163 (31–511) | 150.4 (47–362) | 173 (31–511) | 0.166 |
International normalized ratio | 1.1 (0.73–1.58) | 1.1 (0.91–1.4) | 1.1 (0.73–1.58) | 0.682 |
Albumin, g/dl | 39.5 (29.4–75.6) | 40.3 (32–75.6) | 38.9 (29.4–52.9) | 0.201 |
Order of treatments | ||||
Sorafenib before TACE/TACE before sorafenib/Meanwhile - No. (%) | 52 (44.1%)/62 (52.5%)/4 (3.4%) | 20 (40.8%)/28 (57.1%)/1 (2.1%) | 32 (46.4%)/34 (49.3%)/3 (4.3%) | 0.610 |
Interval between TACE and sorafenib (d) | ||||
Median (Range) | 3 (0–55) | 2 (0–40) | 3 (0–55) | 0.073 |
